Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil.
about
Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Economic evaluations in gastroenterology in Brazil: A systematic review.Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.[Cost-effectiveness in health in Brazil: a systematic review].
P2860
Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@en
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@nl
type
label
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@en
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@nl
prefLabel
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@en
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness analysis of ...... c payer perspective in Brazil.
@en
P2093
Carolina T Tsuchiya
Eduardo Av Santos
Fabio Mr Barros
Hugo Cheinquer
P2860
P2888
P356
10.1186/1478-7547-11-25
P577
2013-10-08T00:00:00Z
P5875
P6179
1008766523